Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Cancer PHGKB

Specific PHGKB|Cancer|Public Health Genomics and Precision Health Knowledge Base (PHGKB)
Last Posted: May 20, 2024
spot light Spotlight

Cancer mRNA vaccines: clinical advances and future opportunities
(Posted May 20, 2024 10AM)

From the abstract: "Thus far, no mRNA-based cancer vaccines have received regulatory approval, although several phase I–II trials have yielded promising results, including in historically poorly immunogenic tumours. Furthermore, many early phase trials testing a wide range of vaccine designs are currently ongoing. In this Review, we describe the advantages of cancer mRNA vaccines and advances in clinical trials using both cell-based and nanoparticle-based delivery methods, with discussions of future combinations and iterations that might optimize the activity of these agents. "

Genomic sequencing research in pediatric cancer care: Decision-making, attitudes, and perceived utility among adolescents and young adults and their parents
(Posted May 18, 2024 4PM)

From the abstract: "Professional guidelines recommend engaging adolescents and young adults (AYAs) in medical decision-making (DM), including whether to undergo genomic sequencing (GS). We explored DM around GS and attitudes after return of GS results among a diverse group of AYAs with cancer and their parents. Methods: We surveyed AYAs with cancer (n=75) and their parents (n=52) six months after receiving GS results through the Texas KidsCanSeq Study. We analyzed AYAs’ DM role in GS research enrollment and their satisfaction with that role. We compared AYAs’ and parents’ self-reported understanding of, attitudes toward, and perceived utility of the AYAs’ GS results. "

Pharmacogenomics, Race, and Treatment Outcome in Pediatric Acute Myeloid Leukemia
(Posted May 18, 2024 4PM)

From the abstract: " Can tailoring the intensity of induction therapy mitigate racial disparities in the outcome of pediatric patients with acute myeloid leukemia (AML)? Findings: In this comparative effectiveness analysis of 86 Black and 359 White patients with AML, Black patients exhibited a higher prevalence of low cytarabine pharmacogenomic 10–single-nucleotide variant (ACS10) scores, which were associated with an unfavorable outcome after initial treatment with low-dose cytarabine-based induction therapy. Augmentation of induction therapy was associated with improved outcome for patients with low ACS10 scores and with no disparity in outcome between Black patients and White patients."

The State of State Biomarker Testing Insurance Coverage Laws
(Posted May 14, 2024 3PM)

From the article:" There has been a recent push for legislation mandating coverage of “biomarker testing” according to evidence that receipt of such testing can depend on race and ethnicity, age, geography, or site of care. A specific type of biomarker testing for cancer subtypes (ie, “tumor profiling”) is becoming particularly important because many newer cancer therapies target specific mutations (eg, EGFR in non–small cell lung cancer, KRAS in colorectal cancer). Although use of biomarker testing is increasing, barriers to access persist. Cost and lack of insurance coverage are common barriers to testing because insurance coverage varies across commercial payers, Medicare, and Medicaid."


news Latest News and Publications
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis. External Web Site Icon
Luca Boscolo Bielo et al. Oncologist 2024
Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia. External Web Site Icon
Andrew Seto et al. Cancers (Basel) 2024 16(9)
Healthcare utilization and behavior changes following workplace genetic testing at a large U.S. healthcare system. External Web Site Icon
Elizabeth Charnysh et al. Genet Med 2024 101160
Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives. External Web Site Icon
Michiel Vlaming et al. Fam Cancer 2024
Optimizing the Use of Next-Generation Sequencing Assays in Patients With Urothelial Carcinoma: Recommendations by the 2023 San Raffaele Retreat Panel. External Web Site Icon
Valentina Tateo et al. Clin Genitourin Cancer 2024 22(4) 102091
Outcomes of a universal germline screening program in a community urology practice. External Web Site Icon
Neil Mendhiratta et al. Clin Genet 2024
Ovarian cancer: identifying and managing familial and genetic risk-summary of new NICE guidance. External Web Site Icon
Eric Slade et al. BMJ 2024 385q807
Targeted sequencing for hereditary breast and ovarian cancer in BRCA1/2-negative families from the Lynch Memorial Biobank reveals complex genetic architecture and phenocopies. External Web Site Icon
Jocelyn N Plowman et al. HGG Adv 2024 100306
Comparison of deep learning models to traditional Cox regression in predicting survival of colon cancer: Based on the SEER database. External Web Site Icon
Zihan Qu et al. J Gastroenterol Hepatol 2024
Development and validation of a random survival forest model for predicting long-term survival of early-stage young breast cancer patients based on the SEER database and an external validation cohort. External Web Site Icon
Lin-Wei Li et al. Am J Cancer Res 2024 14(4) 1609-1621

More

About Cancer PHGKB

Cancer PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to cancer...more

Content Summary

Common Type

Quick Links


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP